Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib Monotherapy or Plus Sintilimab in Advanced Solid Tumors
NCT03903705Phase 2Completed
- Sponsor
- HUTCHMED
- Start
- Apr 2019
- Primary completion
- Nov 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in solid tumor, endometrial cancer (EC), hepatocellular carcinoma (HCC), renal cell carcinoma (RCC), gastric adenocarcinoma, sponsored by HUTCHMED. Started Apr 2019; status: completed.
02
Drugs
fruquintinib
03
Conditions
solid tumorendometrial cancer (EC)hepatocellular carcinoma (HCC)renal cell carcinoma (RCC)gastric adenocarcinoma
Beyond the preview
Go deeper on NCT03903705.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03903705.